FTRE vs IRWD
FTRE: Fortrea is a dedicated global CRO focused on clinical trial execution and commercialization services to help biopharmaceutical companies bring new therapies to market. IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline for rare intestinal diseases.
Side-by-side fundamentals
| Metric | FTRE | IRWD | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $19.17 | $4.23 | |
| Market cap as of 2026-08-03 | $1.8B | $696M | |
| P/E as of 2026-08-03 | n/a | 7.23 | |
| PEG as of 2026-08-03 | 0.45 | n/a | |
| Net margin as of 2026-08-03 | -16.5% | +28.3% | IRWD higher |
| Gross margin as of 2026-08-03 | +18.9% | +100.0% | IRWD higher |
| Operating margin as of 2026-08-03 | -13.1% | +55.4% | IRWD higher |
| ROE as of 2026-08-03 | -79.1% | +29.3% | IRWD higher |
| ROA as of 2026-08-03 | -16.3% | +26.0% | IRWD higher |
| Debt / equity as of 2026-08-03 | 2.00 | 0.56 | IRWD lower |
| Revenue growth (YoY) as of 2026-08-03 | +0.9% | +13.8% | IRWD higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | -10.3% | FTRE higher |
| Beta as of 2026-08-03 | 1.82 | 1.11 | |
| 1-year return as of 2026-07-31 close | +234.0% | +456.6% | IRWD higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.